Even before officially taking control of the 110th Congress, Democratic leaders promised to give priority to a broad range of healthcare issues, including coverage of an estimated 47 million uninsured Americans, expanded stem cell research, and changes to the Medicare prescription drug benefit program. At stake this year for clinical laboratories and pathologists are two particularly critical issues: competitive bidding and increased regulation of both "home brew" lab tests and a subgroup of complex molecular tests that the FDA calls In Vitro Diagnostic Multivariate Index Assays (IVDMIAs).

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

February 2007 - Table of Contents

LIR February 2007 (full PDF issue)

Lab Industry Follows Pharma Into Direct-to-Consumer Marketing

Lab Execs Map Out Competitive Strategies

Sonic Deviates From Offshore Strategy, Acquires Remaining 18% of CPL

Horizon/LabCorp Deal Ousts Bio-Reference

RedPath Builds on a Convergence of Technology

New Congress to Influence Critical Laboratory, Pathology Issues

Cutting Out the Middle Man? Major Lab Players Target Patients in New Media Campaigns

Spectrum to Use Thomson’s MercuryMD Mobile EHR System

United Will Cover Oncotype DX Testing

Lab Stocks Rose 29% In 2006; Genomic Health Was Best Performer

FDA to Hold Meeting on IVDMIAs